Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DVA stock price vs WST: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WST's multiple
Needs WST P/E.
Implied fair value · at DVA's multiple
Needs DVA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DAVITA INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
WEST PHARMACEUTICAL SERVICES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
QUEST DIAGNOSTICS INC
DVA vs DGX
BAXTER INTERNATIONAL INC
DVA vs BAX
MCKESSON CORP
DVA vs MCK
Cigna Group
DVA vs CI
LABCORP HOLDINGS INC.
DVA vs LH
APTARGROUP, INC.
DVA vs ATR
BECTON DICKINSON & CO
DVA vs BDX
ICU MEDICAL INC/DE
DVA vs ICUI
TELEFLEX INC
DVA vs TFX
CARDINAL HEALTH INC
DVA vs CAH
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DVA can narrow its margin and leverage gaps toward WST (improving margins and reducing Net Debt/EBITDA), then consider accumulation because WST-implied P/E suggests meaningful upside (~$388.28 implied); if you believe margins and leverage will persist, then avoid or underweight because the valuation gap likely reflects real profitability and balance-sheet differences.
DVA's implied price using WST multiples is $388.28 (159.8% upside versus the current $149.45), driven primarily by a large P/E and P/S differential. The current price sits inside DVA's historical band ($134.50 - $164.40) but far below WST-implied range ($388.28 - $1282.04).
Supporting Metrics
